Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Basilea Pharmaceutica Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.

NCT05582187
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Fosmanogepix
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
2
States / cities
Rialto, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Methadone

NCT01582425
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Methadone, Healthy Volunteers
Interventions
Isavuconazole, Methadone
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2012 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia

NCT03604705
View directory record Official record
Conditions
Candidemia
Interventions
APX001
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Sacramento, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia

NCT03138733
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia
Interventions
Ceftobiprole medocaril, Daptomycin
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional

Open Label Study of Ceftobiprole to Evaluate Pharmacokinetics in Adults Hospitalized in the ICU

NCT00770978
View directory record Official record
Conditions
ICU
Interventions
ceftobiprole q12h, ceftobiprole q8h
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Chicago, Illinois • Beech Grove, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole

NCT01660477
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Lopinavir/Ritonavir, Healthy Volunteers
Interventions
Isavuconazole, Lopinavir/ritonavir
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

NCT01752920
View directory record Official record
Conditions
Solid Tumor
Interventions
Derazantinib low dose range, Derazantinib middle dose range, Derazantinib high dose range, Derazantinib at recommended phase 2 dose (RP2D)
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 1, 2026, 8:03 PM EDT
Terminated Phase 1 Interventional Results available

Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics

NCT02527681
View directory record Official record
Conditions
Bacterial Infections
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
Up to 3 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Loma Linda, California • Los Angeles, California • South Bend, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 1, 2026, 8:03 PM EDT
Terminated Phase 1 Interventional Results available

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

NCT03250299
View directory record Official record
Conditions
Glioblastoma, MGMT-Unmethylated Glioblastoma
Interventions
Microtubule-Targeted Agent BAL101553, Radiation Therapy
Drug · Radiation
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age

NCT05856227
View directory record Official record
Conditions
Neonatal Sepsis
Interventions
Ceftobiprole medocaril
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
3 Days to 3 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Evanston, Illinois • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VNRX-7145 SAD/MAD Safety and PK in Healthy Adult Volunteers

NCT04243863
View directory record Official record
Conditions
Healthy Volunteers
Interventions
VNRX-7145, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma

NCT04604132
View directory record Official record
Conditions
Gastric Adenocarcinoma
Interventions
Derazantinib, Derazantinib-paclitaxel-ramucirumab combination
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Orlando, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects

NCT01813461
View directory record Official record
Conditions
Pharmacokinetics of 14C-labeled Isavuconazole, Healthy Subjects
Interventions
14C-labeled prodrug isavuconazonium sulfate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects

NCT01651325
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Dextromethorphan, Healthy Adult Volunteers
Interventions
Isavuconazole, dextromethorphan
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion

NCT01635972
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Bupropion, Healthy Volunteers
Interventions
Isavuconazole, bupropion hydrochloride
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi

NCT00634049
View directory record Official record
Conditions
Aspergillosis, Invasive Fungal Infections
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Duarte, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

NCT00412893
View directory record Official record
Conditions
Aspergillosis, Invasive Fungal Infection
Interventions
Isavuconazole, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

NCT05488678
View directory record Official record
Conditions
Pharmacokinetics
Interventions
VNRX-7145, Ceftibuten
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years to 82 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects

NCT02059590
View directory record Official record
Conditions
Pharmacokinetics of 14C-labeled Isavuconazonium Sulfate, Healthy Subjects
Interventions
Pyridinylmethyl-14C-labeled isavuconazonium sulfate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Digoxin

NCT01582412
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Digoxin, Healthy Volunteers
Interventions
Isavuconazole, digoxin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate

NCT01884636
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Methotrexate, Pharmacokinetics of 7-hydroxymethotrexate, Healthy Subjects
Interventions
isavuconazole, methotrexate
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Isavuconazole and Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone

NCT01597986
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ethinyl Estradiol and Norethindrone, Healthy Volunteers
Interventions
isavuconazole, Oral Contraceptive (ethinyl estradiol / norethindrone)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
50 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 1, 2026, 8:03 PM EDT
Terminated Phase 2 Interventional Results available

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

NCT04240886
View directory record Official record
Conditions
Invasive Fungal Infections
Interventions
fosmanogepix
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Duarte, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 1, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Results available

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

NCT03230318
View directory record Official record
Conditions
Intrahepatic Cholangiocarcinoma, Combined Hepatocellular and Cholangiocarcinoma
Interventions
derazantinib
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 1, 2026, 8:03 PM EDT